8-KOther Events

AMGEN INC 8-K Report (Apr 8, 1997)

Filed April 8, 1997For Securities:AMGN

Summary

This 8-K filing from Amgen Inc. on April 8, 1997, relates to its financial reporting and business operations, specifically indicating the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 1996. This is a routine but crucial filing for investors as it provides a comprehensive overview of the company's financial health, operational performance, and strategic direction. The 10-K filing contains audited financial statements, management's discussion and analysis (MD&A) of financial condition and results of operations, risk factors, and other material information. For investors, this document is a primary source for understanding Amgen's past performance, current standing, and future outlook, including its product portfolio, research and development pipeline, and market positioning within the biotechnology sector.

Key Highlights

  • 1Amgen Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 1996.
  • 2The 8-K filing serves as notification of the 10-K's submission to the SEC.
  • 3The 10-K is a comprehensive annual disclosure document.
  • 4Investors can find audited financial statements within the 10-K.
  • 5Management's Discussion and Analysis (MD&A) provides insights into financial performance and condition.
  • 6Risk factors and other material business information are detailed in the filing.
  • 7This filing is essential for understanding Amgen's financial health and operational overview from 1996.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report that Amgen Inc. has submitted its Annual Report on Form 10-K for the fiscal year ended December 31, 1996, to the U.S. Securities and Exchange Commission (SEC).

Investors can expect to find detailed audited financial statements for the fiscal year 1996, Management's Discussion and Analysis (MD&A) of financial condition and results of operations, a description of Amgen's business, risk factors facing the company, information about its legal proceedings, and details regarding its executive officers and directors.

The Form 10-K is a critical document for shareholders as it provides a comprehensive and audited overview of the company's financial performance, strategic direction, and potential risks. It allows investors to make informed decisions about their investment in Amgen by understanding the company's historical results and future prospects.

No, this 8-K filing itself does not typically contain new financial results or operational updates. Its purpose is solely to announce the filing of the more detailed 10-K report. All the new substantive information regarding financial results and operations for the fiscal year 1996 will be found within the actual 10-K report that was filed on the same date.